Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road, Shenyang 110016, China.
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences (ICMS), University of Macau, Macau, China.
J Control Release. 2022 Nov;351:656-666. doi: 10.1016/j.jconrel.2022.09.049. Epub 2022 Oct 6.
Adrenergic nerves, which are innervated in the tumor, regulate tumor initiation, angiogenesis, and the establishment of the tumor immunosuppressive microenvironment. The study aimed to evaluate the effectiveness of propranolol liposomes (Lipo pro) in inhibiting adrenergic nerve signaling in cancer therapy. Lipo pro significantly regulated the distribution of tumor microenvironment adrenergic nerves, tumor blood vessels, and immunosuppressive microenvironment. Furthermore, it displayed considerable therapeutic effects on prostatic cancer, pancreatic ductal adenocarcinoma, and melanoma. The combination therapeutic regimen, in which Lipo pro was the primary treatment and was supplemented by chemotherapy, showed significant advantages over any single treatment, effectively restraining tumor growth in situ and metastasis, thereby prolonging the survival of mice. This study established a proof-of-concept by targeting tumor adrenergic nerve signaling for cancer therapy.
肾上腺素能神经在肿瘤中受支配，调节肿瘤的发生、血管生成和肿瘤免疫抑制微环境的建立。本研究旨在评估普萘洛尔脂质体（Lipo pro）在抑制癌症治疗中肾上腺素能神经信号方面的有效性。Lipo pro 显著调节了肿瘤微环境肾上腺素能神经、肿瘤血管和免疫抑制微环境的分布。此外，它对前列腺癌、胰腺导管腺癌和黑色素瘤具有相当的治疗效果。联合治疗方案中，Lipo pro 是主要治疗方法，并辅以化疗，与任何单一治疗相比具有显著优势，有效抑制原位和转移肿瘤生长，从而延长了小鼠的生存时间。本研究通过针对肿瘤肾上腺素能神经信号进行癌症治疗，为这一概念提供了初步验证。
